Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 155

1.

High-dimensional single-cell proteomics analysis identifies immune checkpoint signatures and therapeutic targets in ulcerative colitis.

Fuchs S, Sawas N, Staedler N, Schubert DA, D'Andrea A, Zeiser R, Piali L, Hruz P, Frei AP.

Eur J Immunol. 2018 Dec 22. doi: 10.1002/eji.201847862. [Epub ahead of print]

PMID:
30578679
2.

Mechanisms of immune escape after allogeneic hematopoietic cell transplantation.

Zeiser R, Vago L.

Blood. 2018 Dec 21. pii: blood-2018-10-846824. doi: 10.1182/blood-2018-10-846824. [Epub ahead of print]

PMID:
30578254
3.

Editorial: Non-coding RNAs and Graft versus Host Disease.

Reddy P, Zeiser R.

Front Immunol. 2018 Nov 20;9:2713. doi: 10.3389/fimmu.2018.02713. eCollection 2018. No abstract available.

4.

Biology-driven developments in the therapy of acute graft-versus-host disease.

Zeiser R.

Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):236-241. doi: 10.1182/asheducation-2018.1.236. Review.

PMID:
30504316
5.

Graft-versus-host disease, but not graft-versus-leukemia immunity, is mediated by GM-CSF-licensed myeloid cells.

Tugues S, Amorim A, Spath S, Martin-Blondel G, Schreiner B, De Feo D, Lutz M, Guscetti F, Apostolova P, Haftmann C, Hasselblatt P, Núñez NG, Hottiger MO, van den Broek M, Manz MG, Zeiser R, Becher B.

Sci Transl Med. 2018 Nov 28;10(469). pii: eaat8410. doi: 10.1126/scitranslmed.aat8410.

PMID:
30487251
6.
7.

miR-146a Controls Immune Response in the Melanoma Microenvironment.

Mastroianni J, Stickel N, Andrlova H, Hanke K, Melchinger W, Duquesne S, Schmidt D, Falk M, Andrieux G, Pfeifer D, Dierbach H, Schmitt-Graeff A, Meiss F, Boerries M, Zeiser R.

Cancer Res. 2019 Jan 1;79(1):183-195. doi: 10.1158/0008-5472.CAN-18-1397. Epub 2018 Nov 13.

PMID:
30425059
8.

Allogeneic transplantation of multiple myeloma patients may allow long-term survival in carefully selected patients with acceptable toxicity and preserved quality of life.

Greil C, Engelhardt M, Ihorst G, Schoeller K, Bertz H, Marks R, Zeiser R, Duyster J, Einsele H, Finke J, Wäsch R.

Haematologica. 2018 Sep 20. pii: haematol.2018.200881. doi: 10.3324/haematol.2018.200881. [Epub ahead of print]

9.

Cobimetinib (GDC-0973, XL518).

Andrlová H, Zeiser R, Meiss F.

Recent Results Cancer Res. 2018;211:177-186. doi: 10.1007/978-3-319-91442-8_12. Review.

PMID:
30069767
10.

Vismodegib.

Meiss F, Andrlová H, Zeiser R.

Recent Results Cancer Res. 2018;211:125-139. doi: 10.1007/978-3-319-91442-8_9. Review.

PMID:
30069764
11.

Trametinib (GSK1120212).

Zeiser R, Andrlová H, Meiss F.

Recent Results Cancer Res. 2018;211:91-100. doi: 10.1007/978-3-319-91442-8_7. Review.

PMID:
30069762
12.

Ruxolitinib.

Ajayi S, Becker H, Reinhardt H, Engelhardt M, Zeiser R, von Bubnoff N, Wäsch R.

Recent Results Cancer Res. 2018;212:119-132. doi: 10.1007/978-3-319-91439-8_6.

PMID:
30069628
13.

Decitabine in combination with donor lymphocyte infusions can induce remissions in relapsed myeloid malignancies with higher leukemic burden after allogeneic hematopoietic cell transplantation.

Sommer S, Cruijsen M, Claus R, Bertz H, Wäsch R, Marks R, Zeiser R, Bogatyreva L, Blijlevens NMA, May A, Duyster J, Huls G, van der Velden WJFM, Finke J, Lübbert M.

Leuk Res. 2018 Sep;72:20-26. doi: 10.1016/j.leukres.2018.07.005. Epub 2018 Jul 7.

PMID:
30064039
14.

P2Y2R Signaling Is Involved in the Onset of Glomerulonephritis.

Rennert L, Zschiedrich S, Sandner L, Hartleben B, Cicko S, Ayata CK, Meyer C, Zech A, Zeiser R, Huber TB, Idzko M, Grahammer F.

Front Immunol. 2018 Jul 16;9:1589. doi: 10.3389/fimmu.2018.01589. eCollection 2018.

15.

Impact of Lung Function on Bronchiolitis Obliterans Syndrome and Outcome after Allogeneic Hematopoietic Cell Transplantation with Reduced-Intensity Conditioning.

Duque-Afonso J, Ihorst G, Waterhouse M, Zeiser R, Wäsch R, Bertz H, Müller-Quernheim J, Finke J, Marks R, Prasse A.

Biol Blood Marrow Transplant. 2018 Nov;24(11):2277-2284. doi: 10.1016/j.bbmt.2018.06.024. Epub 2018 Jun 28.

PMID:
29964193
16.

Erratum: Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells.

Mathew NR, Baumgartner F, Braun L, O'Sullivan D, Thomas S, Waterhouse M, Müller TA, Hanke K, Taromi S, Apostolova P, Illert AL, Melchinger W, Duquesne S, Schmitt-Graeff A, Osswald L, Yan KL, Weber A, Tugues S, Spath S, Pfeifer D, Follo M, Claus R, Lübbert M, Rummelt C, Bertz H, Wäsch R, Haag J, Schmidts A, Schultheiss M, Bettinger D, Thimme R, Ullrich E, Tanriver Y, Vuong GL, Arnold R, Hemmati P, Wolf D, Ditschkowski M, Jilg C, Wilhelm K, Leiber C, Gerull S, Halter J, Lengerke C, Pabst T, Schroeder T, Kobbe G, Rösler W, Doostkam S, Meckel S, Stabla K, Metzelder SK, Halbach S, Brummer T, Hu Z, Dengjel J, Hackanson B, Schmid C, Holtick U, Scheid C, Spyridonidis A, Stölzel F, Ordemann R, Müller LP, Sicre-de-Fontbrune F, Ihorst G, Kuball J, Ehlert JE, Feger D, Wagner EM, Cahn JY, Schnell J, Kuchenbauer F, Bunjes D, Chakraverty R, Richardson S, Gill S, Kröger N, Ayuk F, Vago L, Ciceri F, Müller AM, Kondo T, Teshima T, Klaeger S, Kuster B, Kim DDH, Weisdorf D, van der Velden W, Dörfel D, Bethge W, Hilgendorf I, Hochhaus A, Andrieux G, Börries M, Busch H, Magenau J, Reddy P, Labopin M, Antin JH, Henden AS, Hill GR, Kennedy GA, Bar M, Sarma A, McLornan D, Mufti G, Oran B, Rezvani K, Shah O, Negrin RS, Nagler A, Prinz M, Burchert A, Neubauer A, Beelen D, Mackensen A, von Bubnoff N, Herr W, Becher B, Socié G, Caligiuri MA, Ruggiero E, Bonini C, Häcker G, Duyster J, Finke J, Pearce E, Blazar BR, Zeiser R.

Nat Med. 2018 Apr 10;24(4):526. doi: 10.1038/nm0418-526c.

PMID:
29634689
17.

Detection of major histocompatibility complex molecules in processed allogeneic bone blocks for use in alveolar ridge reconstruction.

Fretwurst T, Gad LM, Steinberg T, Schmal H, Zeiser R, Amler AK, Nelson K, Altmann B.

Oral Surg Oral Med Oral Pathol Oral Radiol. 2018 Mar 20. pii: S2212-4403(18)30054-3. doi: 10.1016/j.oooo.2018.01.018. [Epub ahead of print]

PMID:
29571656
18.

Oncogenic JAK2V617F causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms.

Prestipino A, Emhardt AJ, Aumann K, O'Sullivan D, Gorantla SP, Duquesne S, Melchinger W, Braun L, Vuckovic S, Boerries M, Busch H, Halbach S, Pennisi S, Poggio T, Apostolova P, Veratti P, Hettich M, Niedermann G, Bartholomä M, Shoumariyeh K, Jutzi JS, Wehrle J, Dierks C, Becker H, Schmitt-Graeff A, Follo M, Pfeifer D, Rohr J, Fuchs S, Ehl S, Hartl FA, Minguet S, Miething C, Heidel FH, Kröger N, Triviai I, Brummer T, Finke J, Illert AL, Ruggiero E, Bonini C, Duyster J, Pahl HL, Lane SW, Hill GR, Blazar BR, von Bubnoff N, Pearce EL, Zeiser R.

Sci Transl Med. 2018 Feb 21;10(429). pii: eaam7729. doi: 10.1126/scitranslmed.aam7729.

PMID:
29467301
19.

Neutrophils provide cellular communication between ileum and mesenteric lymph nodes at graft-versus-host disease onset.

Hülsdünker J, Ottmüller KJ, Neeff HP, Koyama M, Gao Z, Thomas OS, Follo M, Al-Ahmad A, Prinz G, Duquesne S, Dierbach H, Kirschnek S, Lämmermann T, Blaser MJ, Fife BT, Blazar BR, Beilhack A, Hill GR, Häcker G, Zeiser R.

Blood. 2018 Apr 19;131(16):1858-1869. doi: 10.1182/blood-2017-10-812891. Epub 2018 Feb 20.

PMID:
29463561
20.

B-cell targeting in chronic graft-versus-host disease.

Zeiser R, Sarantopoulos S, Blazar BR.

Blood. 2018 Mar 29;131(13):1399-1405. doi: 10.1182/blood-2017-11-784017. Epub 2018 Feb 1. Review.

PMID:
29437591
21.

Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells.

Mathew NR, Baumgartner F, Braun L, O'Sullivan D, Thomas S, Waterhouse M, Müller TA, Hanke K, Taromi S, Apostolova P, Illert AL, Melchinger W, Duquesne S, Schmitt-Graeff A, Osswald L, Yan KL, Weber A, Tugues S, Spath S, Pfeifer D, Follo M, Claus R, Lübbert M, Rummelt C, Bertz H, Wäsch R, Haag J, Schmidts A, Schultheiss M, Bettinger D, Thimme R, Ullrich E, Tanriver Y, Vuong GL, Arnold R, Hemmati P, Wolf D, Ditschkowski M, Jilg C, Wilhelm K, Leiber C, Gerull S, Halter J, Lengerke C, Pabst T, Schroeder T, Kobbe G, Rösler W, Doostkam S, Meckel S, Stabla K, Metzelder SK, Halbach S, Brummer T, Hu Z, Dengjel J, Hackanson B, Schmid C, Holtick U, Scheid C, Spyridonidis A, Stölzel F, Ordemann R, Müller LP, Sicre-de-Fontbrune F, Ihorst G, Kuball J, Ehlert JE, Feger D, Wagner EM, Cahn JY, Schnell J, Kuchenbauer F, Bunjes D, Chakraverty R, Richardson S, Gill S, Kröger N, Ayuk F, Vago L, Ciceri F, Müller AM, Kondo T, Teshima T, Klaeger S, Kuster B, Kim DDH, Weisdorf D, van der Velden W, Dörfel D, Bethge W, Hilgendorf I, Hochhaus A, Andrieux G, Börries M, Busch H, Magenau J, Reddy P, Labopin M, Antin JH, Henden AS, Hill GR, Kennedy GA, Bar M, Sarma A, McLornan D, Mufti G, Oran B, Rezvani K, Shah O, Negrin RS, Nagler A, Prinz M, Burchert A, Neubauer A, Beelen D, Mackensen A, von Bubnoff N, Herr W, Becher B, Socié G, Caligiuri MA, Ruggiero E, Bonini C, Häcker G, Duyster J, Finke J, Pearce E, Blazar BR, Zeiser R.

Nat Med. 2018 Mar;24(3):282-291. doi: 10.1038/nm.4484. Epub 2018 Feb 12. Erratum in: Nat Med. 2018 Apr 10;24(4):526.

PMID:
29431743
22.

Acute Graft-versus-Host Disease.

Zeiser R, Blazar BR.

N Engl J Med. 2018 Feb 8;378(6):586. doi: 10.1056/NEJMc1716969. No abstract available.

PMID:
29414273
23.

The Role of MicroRNAs in Myeloid Cells during Graft-versus-Host Disease.

Chen S, Zeiser R.

Front Immunol. 2018 Jan 23;9:4. doi: 10.3389/fimmu.2018.00004. eCollection 2018. Review.

24.

Immune modulatory effects of statins.

Zeiser R.

Immunology. 2018 May;154(1):69-75. doi: 10.1111/imm.12902. Epub 2018 Feb 20. Review.

PMID:
29392731
25.

Introduction to a review series on strategies to improve GVL effects.

Zeiser R.

Blood. 2018 Mar 8;131(10):1039. doi: 10.1182/blood-2017-11-814467. Epub 2018 Jan 22. No abstract available.

PMID:
29358178
26.

Ruxolitinib for the treatment of patients with steroid-refractory GVHD: an introduction to the REACH  trials.

Jagasia M, Zeiser R, Arbushites M, Delaite P, Gadbaw B, Bubnoff NV.

Immunotherapy. 2018 Apr;10(5):391-402. doi: 10.2217/imt-2017-0156. Epub 2018 Jan 10.

PMID:
29316837
27.

Pathophysiology of Chronic Graft-versus-Host Disease and Therapeutic Targets.

Zeiser R, Blazar BR.

N Engl J Med. 2017 Dec 28;377(26):2565-2579. doi: 10.1056/NEJMra1703472. Review. No abstract available.

PMID:
29281578
28.

Negative regulation of TGF-β1-induced MKK6-p38 and MEK-ERK signalling and epithelial-mesenchymal transition by Rac1b.

Witte D, Otterbein H, Förster M, Giehl K, Zeiser R, Lehnert H, Ungefroren H.

Sci Rep. 2017 Dec 11;7(1):17313. doi: 10.1038/s41598-017-15170-6.

29.

MicroRNA-100 Suppresses Chronic Vascular Inflammation by Stimulation of Endothelial Autophagy.

Pankratz F, Hohnloser C, Bemtgen X, Jaenich C, Kreuzaler S, Hoefer I, Pasterkamp G, Mastroianni J, Zeiser R, Smolka C, Schneider L, Martin J, Juschkat M, Helbing T, Moser M, Bode C, Grundmann S.

Circ Res. 2018 Feb 2;122(3):417-432. doi: 10.1161/CIRCRESAHA.117.311428. Epub 2017 Dec 5.

PMID:
29208678
30.

Acute Graft-versus-Host Disease - Biologic Process, Prevention, and Therapy.

Zeiser R, Blazar BR.

N Engl J Med. 2017 Nov 30;377(22):2167-2179. doi: 10.1056/NEJMra1609337. Review. No abstract available.

31.

The Atypical Kinase RIOK1 Promotes Tumor Growth and Invasive Behavior.

Weinberg F, Reischmann N, Fauth L, Taromi S, Mastroianni J, Köhler M, Halbach S, Becker AC, Deng N, Schmitz T, Uhl FM, Herbener N, Riedel B, Beier F, Swarbrick A, Lassmann S, Dengjel J, Zeiser R, Brummer T.

EBioMedicine. 2017 Jun;20:79-97. doi: 10.1016/j.ebiom.2017.04.015. Epub 2017 Apr 12.

32.

MicroRNA-146a reduces MHC-II expression via targeting JAK/STAT signaling in dendritic cells after stem cell transplantation.

Stickel N, Hanke K, Marschner D, Prinz G, Köhler M, Melchinger W, Pfeifer D, Schmitt-Graeff A, Brummer T, Heine A, Brossart P, Wolf D, von Bubnoff N, Finke J, Duyster J, Ferrara J, Salzer U, Zeiser R.

Leukemia. 2017 Dec;31(12):2732-2741. doi: 10.1038/leu.2017.137. Epub 2017 May 9.

33.

Biglycan expression in the melanoma microenvironment promotes invasiveness via increased tissue stiffness inducing integrin-β1 expression.

Andrlová H, Mastroianni J, Madl J, Kern JS, Melchinger W, Dierbach H, Wernet F, Follo M, Technau-Hafsi K, Has C, Rao Mittapalli V, Idzko M, Herr R, Brummer T, Ungefroren H, Busch H, Boerries M, Narr A, Ihorst G, Vennin C, Schmitt-Graeff A, Minguet S, Timpson P, Duyster J, Meiss F, Römer W, Zeiser R.

Oncotarget. 2017 Jun 27;8(26):42901-42916. doi: 10.18632/oncotarget.17160.

34.

Pregnancy Specific β-1 Glycoprotein 1 is Expressed in Pancreatic Ductal Adenocarcinoma and its Subcellular Localization Correlates with Overall Survival.

Shahinian JH, Fuellgraf H, Tholen S, Mastroianni J, Knopf JD, Kuehs M, Mayer B, Schlimpert M, Kulemann B, Kuesters S, Hoeppner J, Wellner UF, Werner M, Hopt UT, Zeiser R, Bronsert P, Schilling O.

J Cancer. 2016 Oct 17;7(14):2018-2027. eCollection 2016.

35.

CXCR4 antagonists suppress small cell lung cancer progression.

Taromi S, Kayser G, Catusse J, von Elverfeldt D, Reichardt W, Braun F, Weber WA, Zeiser R, Burger M.

Oncotarget. 2016 Dec 20;7(51):85185-85195. doi: 10.18632/oncotarget.13238.

36.

Introduction to a review series on chronic GVHD: from pathogenic B-cell receptor signaling to novel therapeutic targets.

Zeiser R, Negrin RS.

Blood. 2017 Jan 5;129(1):1-2. doi: 10.1182/blood-2016-10-735696. Epub 2016 Nov 7. No abstract available.

37.

The Role of Purine Metabolites as DAMPs in Acute Graft-versus-Host Disease.

Apostolova P, Zeiser R.

Front Immunol. 2016 Oct 21;7:439. eCollection 2016. Review.

38.

Pathogenesis of acute graft-versus-host disease: from intestinal microbiota alterations to donor T cell activation.

Zeiser R, Socié G, Blazar BR.

Br J Haematol. 2016 Oct;175(2):191-207. doi: 10.1111/bjh.14295. Epub 2016 Sep 13. Review.

PMID:
27619472
39.

Allogeneic hematopoietic cell transplantation with double alkylating agents containing reduced-intensity conditioning for patients ⩾60 years with advanced AML/MDS.

Bertz H, Lübbert M, Ohneberg K, Zeiser R, Wäsch R, Marks R, Finke J.

Leukemia. 2016 Dec;30(12):2426-2429. doi: 10.1038/leu.2016.248. Epub 2016 Aug 30. No abstract available.

PMID:
27573558
40.

Matching for the nonconventional MHC-I MICA gene significantly reduces the incidence of acute and chronic GVHD.

Carapito R, Jung N, Kwemou M, Untrau M, Michel S, Pichot A, Giacometti G, Macquin C, Ilias W, Morlon A, Kotova I, Apostolova P, Schmitt-Graeff A, Cesbron A, Gagne K, Oudshoorn M, van der Holt B, Labalette M, Spierings E, Picard C, Loiseau P, Tamouza R, Toubert A, Parissiadis A, Dubois V, Lafarge X, Maumy-Bertrand M, Bertrand F, Vago L, Ciceri F, Paillard C, Querol S, Sierra J, Fleischhauer K, Nagler A, Labopin M, Inoko H, von dem Borne PA, Kuball J, Ota M, Katsuyama Y, Michallet M, Lioure B, Peffault de Latour R, Blaise D, Cornelissen JJ, Yakoub-Agha I, Claas F, Moreau P, Milpied N, Charron D, Mohty M, Zeiser R, Socié G, Bahram S.

Blood. 2016 Oct 13;128(15):1979-1986. Epub 2016 Aug 22.

41.

Anti-thymocyte globulin-induced hyperbilirubinemia in patients with myelofibrosis undergoing allogeneic hematopoietic cell transplantation.

Ecsedi M, Schmohl J, Zeiser R, Drexler B, Halter J, Medinger M, Duyster J, Kanz L, Passweg J, Finke J, Bethge W, Lengerke C.

Ann Hematol. 2016 Oct;95(10):1627-36. doi: 10.1007/s00277-016-2758-z. Epub 2016 Aug 2.

PMID:
27480090
42.

Loss of LSR affects epithelial barrier integrity and tumor xenograft growth of CaCo-2 cells.

Czulkies BA, Mastroianni J, Lutz L, Lang S, Schwan C, Schmidt G, Lassmann S, Zeiser R, Aktories K, Papatheodorou P.

Oncotarget. 2017 Jun 6;8(23):37009-37022. doi: 10.18632/oncotarget.10425.

43.

An orthotopic mouse model of small cell lung cancer reflects the clinical course in patients.

Taromi S, Kayser G, von Elverfeldt D, Reichardt W, Braun F, Weber WA, Zeiser R, Burger M.

Clin Exp Metastasis. 2016 Oct;33(7):651-60. doi: 10.1007/s10585-016-9808-8. Epub 2016 Jul 6.

PMID:
27380917
44.

In Vivo Myeloperoxidase Imaging and Flow Cytometry Analysis of Intestinal Myeloid Cells.

Hülsdünker J, Zeiser R.

Methods Mol Biol. 2016;1422:161-7. doi: 10.1007/978-1-4939-3603-8_15.

PMID:
27246031
45.

Peri-alloHCT IL-33 administration expands recipient T-regulatory cells that protect mice against acute GVHD.

Matta BM, Reichenbach DK, Zhang X, Mathews L, Koehn BH, Dwyer GK, Lott JM, Uhl FM, Pfeifer D, Feser CJ, Smith MJ, Liu Q, Zeiser R, Blazar BR, Turnquist HR.

Blood. 2016 Jul 21;128(3):427-39. doi: 10.1182/blood-2015-12-684142. Epub 2016 May 24.

46.

PO-33 - Heparin suppresses progression of small cell lung cancer (SCLC) in an orthotopic mouse model.

Taromi S, Catusse J, Elverfeldt DV, Reichardt W, Ledig B, Zeiser R, Burger M.

Thromb Res. 2016 Apr;140 Suppl 1:S188. doi: 10.1016/S0049-3848(16)30166-9. Epub 2016 Apr 8.

PMID:
27161720
47.

Origin, fate and dynamics of macrophages at central nervous system interfaces.

Goldmann T, Wieghofer P, Jordão MJ, Prutek F, Hagemeyer N, Frenzel K, Amann L, Staszewski O, Kierdorf K, Krueger M, Locatelli G, Hochgerner H, Zeiser R, Epelman S, Geissmann F, Priller J, Rossi FM, Bechmann I, Kerschensteiner M, Linnarsson S, Jung S, Prinz M.

Nat Immunol. 2016 Jul;17(7):797-805. doi: 10.1038/ni.3423. Epub 2016 May 2.

48.

Gab2 is essential for Bcr-Abl-mediated leukemic transformation and hydronephrosis in a chronic myeloid leukemia mouse model.

Halbach S, Köhler M, Uhl FM, Huber J, Zeiser R, Koschmieder S, Aumann K, Brummer T.

Leukemia. 2016 Sep;30(9):1942-5. doi: 10.1038/leu.2016.92. Epub 2016 Apr 29. No abstract available.

PMID:
27125306
49.

Unlocking the Potential of Purinergic Signaling in Transplantation.

Zeiser R, Robson SC, Vaikunthanathan T, Dworak M, Burnstock G.

Am J Transplant. 2016 Oct;16(10):2781-2794. doi: 10.1111/ajt.13801. Epub 2016 Apr 28. Review.

50.

Preclinical models of acute and chronic graft-versus-host disease: how predictive are they for a successful clinical translation?

Zeiser R, Blazar BR.

Blood. 2016 Jun 23;127(25):3117-26. doi: 10.1182/blood-2016-02-699082. Epub 2016 Mar 18.

Supplemental Content

Loading ...
Support Center